Replies to post #6170 on Provectus Biopharmaceuticals Inc (PVCT)

[vorlon1966]

It's called a stoppage rule.
The DMC will determine the threshold for such a recommended stoppage.
Many in the industry argue that early stoppage may skew the results of a study.
But in some cases where safety is assured and efficacy is supreme then such stoppage is considered ethical in oncology cases and moving the comparator group to the investigational drug advisable.

It's in the FDA rule book.